• Tryp Therapeutics is a pharmaceutical company focused on developing new potential treatments for medical conditions with unmet needs
• The company’s current lead candidates for drug development are a synthetic psychedelic for treating fibromyalgia and eating disorders
• Tryp’s efforts to develop a psychedelic drug candidate are part of a broader scientific movement to use various mind-altering drugs to treat select neurological conditions when paired with the care of a trained therapist
• The company has been preparing to initiate a Phase 2a clinical trial for the psychedelic candidate in partnership with a medical research team at the University of Florida

The idea of using psychedelic, mind-tripping drugs as pharmaceuticals to help improve the quality of people’s lives no longer seems as far out as it once might have during the heyday of the multinational war on drugs. An increasing cadre of investigational science efforts are utilizing psychedelics to determine their potential in creating better medicine for select conditions with neurological-based maladies.

San Diego-based pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is turning its own investigational machinery toward the development of drug candidates TRP-8802, a synthetic psilocybin formulation being aimed at fibromyalgia and certain eating disorders.

The development of TRP-8802 is taking place under Tryp’s trademarked Psilocybin-for-Neuropsychiatric Disorders (PFN(TM)) program, which is also evaluating the potential of synthetic psilocybin for treating neuropsychiatric-based chronic pain conditions and eating disorders, such as binge eating and hypothalamic obesity.

The company is partnering with the University of Florida and lead investigator Jennifer Miller, M.D., for a Phase 2a clinical trial looking into TRP-8802’s safety and efficacy in treating eating disorders.

“The research we’re actually going to be doing at the University of Florida with psilocybin is focusing on a little bit more intense problems than just eating disorders,” Dr. Miller said during an interview with The Dales Report published May 3 (https://ibn.fm/F4kho). “Ultimately, of course, we hope it will help people with overall eating disorders, but first we’re going to focus on people with specific neurologic causes of those eating disorders, primarily something called hyperphagia, where (the patients) just never feel full, so they are constantly wanting to eat.”

Dr. Miller, a professor of pediatrics and endocrinology at the University of Florida, said researchers will look at the efficacy in treating people with uncontrollable eating urges resulting from the genetic disorder PWS, hypothalamic obesity eating disorder resulting from the removal of a brain tumor, and binge eating disorder.

“All of the currently available approved obesity and eating disorder medications are daily medications: you stop taking them, you stop having the efficacy,” Miller said. “Our hope is with psilocybin, … (that) once- or twice-a-year treatments will allow these neural networks to rewire themselves and provide a more chronic treatment, which doesn’t exist right now. … None of the currently available treatments or even past available treatments touch their appetite and fullness.”

Tryp’s ambitions are being fueled by other institutions’ recent studies into psychedelics’ benefits and efforts to open legislative avenues for broader legal use of psychedelics in wellness programs.

Science magazine hailed study results published earlier this month that indicated ecstasy (the compound 3,4-methylenedioxymethamphetamine, or MDMA) alleviated post-traumatic stress disorder (“PTSD”) in a phase 3 clinical trial, branding them a “milestone in efforts to turn psychedelic drugs into mainstream treatments,” particularly because it involved administering a mind-altering drug under the care of a trained therapist (https://ibn.fm/HDaqz).

In the United Kingdom, a recent documentary examined a study by renowned neuropsychopharmacologist David Nutt into uses of psilocybin as a potentially better treatment for depression than commonly prescribed medications (https://ibn.fm/Gcuuy). and researchers at the University of California, Davis report they have achieved a medical breakthrough with their discovery of a psychedelic molecule that doesn’t trigger hallucinations (https://ibn.fm/RLCrm).

In regard to the eating disorders stay at the University of Florida, Tryp President and Chief Science Officer Jim Gilligan, Ph.D. told The Dales Report, “What Tryp is supplying is the psychedelic expertise as a complement … We take luminaries in the field, such as Dr. Miller in eating disorders, and pair with Tryp, and we think that gives us the best likelihood of a positive outcome.”

Gilligan added, “What we’d like to be able to do is, in a way, demystify … and show that, ‘Look, there’s good clinical data’; there’s good reason to believe that there’s an opportunity to do this, and I think the more groups that have success across the spectrum, the better off we’re going to be.”

For more information, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

 

• FingerMotion, a U.S.-based communications technology company focused on China’s enormous marketplace, is steadily building partnerships to help it grow a potential for a billion users
• The company’s latest contract is with China Mobile Fujian, a provincial mobile information service operator
• FingerMotion expects the volume-based SMS agreement to boost its gross profit margin by about 30 percent and potentially lead to additional, similar agreements
• FingerMotion also demonstrated its promise when it secured a collaborative agreement with insurance titan Pacific Life Re that will allow FingerMotion to serve as Pacific Life’s data provider in China

Mobile data and services innovator FingerMotion (OTCQX: FNGR) has taken another step toward rich communication services (“RCS”) and big-data insights expansion in China’s hot market for data applications this year.

The company, which possesses one of only a handful of licenses to access and analyze the mobile data of telecommunications giants China Unicom and China Mobile customers, announced May 18 that it has entered an agreement with China Mobile Fujian that is expected to bring about 30 percent improvement to FingerMotion’s gross margin on its SMS (message texting) business, according to the announcement (https://ibn.fm/kdy9l).

China Mobile Fujian has about 30 million or more online subscribers, which is about 70 percent of the market share in the province of Fujian. The announcement states that large provincial mobile information service operators in China are provisioning resources to take advantage of a marketplace anticipating rapid growth with the introduction of 5G wireless networks, and they may look to FingerMotion SMS subsidiary JiuGe “for guidance and assistance.”

JiuGe was a key part of the contract negotiations between FingerMotion and China Mobile Fujian and expects to continue to secure new contracts with China Mobile. China Mobile and China Unicom’s customer base represents over 1.1 billion phones.

“Our focus over the past year was on improving margins,” FingerMotion CEO Martin Shen stated. “This volume-based agreement is expected to increase our margins from 6.1% to approximately 30% and is a testament to our incredibly talented team that continues to impress our business partners. With SMS demand remaining strong, we are able to meet the new pressures through operational efficiencies but continue to be limited by the capital required to adequately fund operations.”

FingerMotion’s core competency is in mobile payment and recharge platform solutions in China, but as the user base of its primary business continues to grow the company is bringing new value-added technologies to market in order to establish an ecosystem of users with high engagement rates.

The availability of more than a billion Chinese consumers’ data to FingerMotion drew the attention of insurance industry giant Pacific Life’s reinsurance division, which sealed a collaborative agreement with FingerMotion in January that essentially makes FingerMotion the data provider for Pacific Life as it looks for growth opportunities in the Chinese insurance industry (https://ibn.fm/cC2nu).

The data services provided by FingerMotion will be able to serve as a proxy for a credit score system in the country. FingerMotion’s Sapientus database helps derive predictive behavior analytics from the data the company obtains to anticipate consumer habits.

The company expects to file its year-end financial report by the end of the month, and predicts annual revenues will top $16 million (https://ibn.fm/LrTPG).

For more information, visit the company’s website at www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

 

• Asia Broadband Inc., an experienced producer of precious metals is adding key gold mine property acquisitions in Mexico, while concurrently developing a proprietary cryptocurrency exchange
• The exchange will build a mechanism for holders of its gold-backed AABBG token to trade with major cryptocurrencies such as Bitcoin, Ethereum, and Litecoin
• The AABBG tokens launched in March, backed by $30 million in physical gold from the company’s properties
• The company reports it achieved several milestones in regard to the exchange’s development during the past month that were related to its network, platform, design and algorithms
• Asia Broadband expects to test the exchange in August and go live with it in September

Asia Broadband (OTC: AABB), a precious and base metals producer intent on developing a proprietary cryptocurrency exchange following the launch of its gold-backed AABBG cryptocurrency token, is reporting progress on the exchange’s creation. The company is backing its entry with $30 million in physical gold from its properties in Mexico, with the price of each token tied to whatever the existing price of one-tenth (0.1) gram of gold may be plus a 2 percent transaction fee  (https://ibn.fm/xqm2Q).

The AABBG token has dual advantages to purchasers. Though not a “stablecoin”, the token has stablecoin-like stability properties in that it is backed and supported by the company at minimum the .1 gram spot price of gold.  Additionally, the token will also have the price appreciation qualities of typical cryptocurrencies, once the proprietary exchange allows the token to be freely exchangeable.

According to a news release issued May 11 (https://ibn.fm/sU6Y3), the company achieved several milestones during the first month of developing the exchange’s network, platform, design and algorithms. Improvements included adding greater visitor capacity, enabling two-way transfers between the blockchain and the user’s wallet and establishing a more efficient mechanism for adding new currencies, completing the iOS, Android and web version designs, and putting the know your customer (“KYC”) protocols into motion for streamlining user and system processes.

The exchange will allow Asia Broadband wallet users to complete quick, two-way exchanges of their AABBG tokens for major cryptocurrencies such as Bitcoin, Ethereum and Litecoin.

According to the news release, the exchange will also augment transaction fee revenues and make it possible for the price of AABBG to appreciate based on market demand and the limits on the number of tokens in circulation.

Select cryptocurrencies have gained enormous value on the market in recent years despite instability that has seen their values fluctuate, and a growing number of investors has turned to the alternate form of money as a potential source of financial profile increase. Famed investors such as billionaire Stanley Druckenmiller predict that the U.S. dollar is on the verge of losing its status as the world’s reserve currency as the country faces the prospect of having to monetize its debt in order to meet its obligations, and some investors understandably prefer exchanges tethered to physical assets such as gold in order to increase their security and reduce volatility. (https://ibn.fm/PcDJe).

Asia Broadband’s exchange is planned for testing in mid-August and is expected to go live in early September. Before then, the company will work to complete its cold wallet, web versions of the wallet and exchange, transaction fee mechanism, trade platform and reporting system, according to the news release.

The Las Vegas-based company has acquired two mines — one in the Mexican state of Guerrero and another in the state of Colima. Its year-end fiscal report stated the company had a record annual gross profit of $16.8 million during 2020.

For more information, visit the company’s website at www.AsiaBroadbandInc.com.

NOTE TO INVESTORS: The latest news and updates relating to AABB are available in the company’s newsroom https://ibn.fm/AABB

 

• IP attorney Alan M. Weisberg, Esq., a partner of Christopher & Weisberg, to work with company
• HENC committed to ensuring that IP generates maximum return for shareholders
• BlackBox has developed a proprietary cannabis growing system based on aeroponic cultivation technology

Hero Technologies (OTC: HENC), a cannabis company focused on a vertically integrated strategy, announced that it has retained intellectual property attorney Alan M. Weisberg, Esq., a partner of Christopher & Weisberg, P.A. Weisberg will assist and advise the company as it focuses on protecting and monetizing the intellectual property of its subsidiary, BlackBox Systems and Technologies LLC (https://ibn.fm/1BCo9). “Solidifying our cannabis intellectual property rights is essential as we seek to monetize our proprietary growing systems,” said Hero Technologies CEO Gina Serkasevich. “Whether by protecting our competitive advantages—particularly in the cost structure and environmental impact of our cannabis operations—or to potentially license our technology for others to use, we want to ensure that our IP generates maximum return for our shareholders.” A registered patent attorney with more than 30 years of technical experience, Weisberg is a former engineer and consultant for IB and has been a featured presenter for the Daily Business Review‘s Intellectual Property Roundtable. He earned a JD, cum laude, and an MS in information systems from Pace University, and a BSEE degree from the Rochester Institute of Technology. BlackBox has developed a proprietary cannabis growing system based on aeroponic cultivation technology (https://ibn.fm/uqh5r). The system creates ideal cannabis growing conditions with a highly efficient use of materials that increases photosynthesis, produces large plant flowers, and optimizes harvests. The BlackBox system design features a high-pressure nutrient delivery system equipped with a UPS battery back-up. The patented innovations in BlackBox’s grow technology allow for the production of premium-grade cannabis at scale, resulting in increasing margins for both wholesalers and retailers while maintaining the highest consumer standards. Hero Technologies is looking for opportunities to acquire significant greenhouse and warehouse space that it can develop for cannabis cultivation and retail operations. The company plans to use its exclusive BlackBox technology for its cultivation projects. Hero Technologies is a cannabis company working toward a vertically integrated business model. The company owns a majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and cultivation of large flowering plants, creating increased harvest efficiencies. The company’s strategic business plan includes cannabis genetic engineering, farmland for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multi-state operator (“MSO”). For more information, visit the company’s website at www.HeroTechnologiesInc.com. NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://ibn.fm/HENC

• Completed acquisition of Acreage Florida, Inc and related owned and leased real estate assets
• Licensed to operate 35 dispensaries, a processing facility and a cultivation facility in Florida
• Florida cannabis market is poised for tremendous growth and it is forecasted to be a top 5 State by the year 2025

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), the torchbearer for a new, higher standard in the American cannabis industry, has announced its new subsidiary RWB Florida LLC, has completed the acquisition of Acreage Florida, Inc. and the related owned and leased real estate assets (https://ibn.fm/aUG1Q). This deal includes over 15 acres of land, a 114,000 SF facility for cultivation, a 4,000 SF freestanding administrative office building, and eight leased stores in prime locations throughout Florida. RWB is positioning itself to be one of the top three multi-state cannabis operators in the US legal cannabis and hemp market. The Company is on a mission to be the superior and most recognizable cannabis company in the US by holding itself to the highest ethical, manufacturing, education, branding and employment standards. “Our employees are impressed with Red White & Bloom’s commitment to the local communities as they expand their ESO program around the environment, jobs, social justice and governance,” stated Jim Frasier, Florida General Manager for RWB. “We are excited to play a major role in the benefits cannabis can bring to the state of Florida.” The Company is licensed to operate 35 dispensaries, a processing facility, and a cultivation facility in Florida. With 30 double-wide fully enclosed cultivation pods ready to deploy in the state, RWB plans to expedite the opening of additional medical marijuana dispensary locations and the implementation of home delivery (https://ibn.fm/T3R52). “The Florida cannabis market is poised for tremendous growth and is forecasted to be a top 5 State by the year 2025,” said Brad Rogers, CEO of RWB. “With approximately 450,000 medical cannabis patients currently registered in Florida, we see this as an amazing growth opportunity for the Company. Combine this with a population of 20M and we are delighted this deal has been finalized and look forward to delivering the highest quality medical products to the market.” The Company has currently completed or has definitive agreements for acquiring THC licensed entities in Michigan, Illinois, Florida, California, and Massachusetts. Once all acquisitions are completed, RWB will be available in 6 of the top 10 US states. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• AmpliTech was tasked by Amplify My Probe with creating a special cryogenic probe head to facilitate studies on materials, molecules, and drugs
• The probe is expected to help speed up Electron Paramagnetic Resonance experiments by more than 100 times
• AmpliTech will be the exclusive manufacturer for the device, and Amplify My Probe will have sole global distribution rights for at least the first 18 months
• Since uplisting to NASDAQ in February 2021, AmpliTech has raised $30 million, creating a strong balance sheet and cash position for the company and allowing it to stay focused on growth and hedge against future market volatility

AmpliTech Group (NASDAQ: AMPG, AMPGW), a designer, developer and manufacturer of custom and standard state-of-the-art RF components for various markets including commercial, SATCOM, space, defense and military, received a significant developmental order for a special cryogenic probe head used to facilitate studies on materials, molecules, and drugs to treat diseases, among other applications (https://ibn.fm/PYlkm). The order was placed by Amplify My Probe, Ltd., a company that emerged from the Quantum Spin Dynamics group at the London Centre for Nanotechnology and UCLQ, and which specializes in commercializing technology to improve signal to noise ratio in Electron Paramagnetic Resonance (“EPR”) experiments. AmpliTech’s will leverage its proprietary cryogenic low-noise amplifier technology that operates at 5 degrees Kelvin (-450 degrees Fahrenheit), to create the requested probe. The amplifier technology has a low power dissipation and can also be used in quantum computing, nanophysics, and astronomy applications. The exclusive manufacturer for the product will be AmpliTech, with Amplify My Probe having the sole global distribution rights for a term of at least 18 months. Other possible applications include speeding up new drug design, increasing efficiency in catalytic processes, and discovering new materials for future quantum computers. According to Dr. Simenas Mantas, one of the Amplify My Probe team members who designed the EPR cryogenic probe, the device is expected to significantly speed up EPR experiments by amplifying microwave signals and suppressing source noise. We anticipate close to 100x speedup of the experiments. Such an improvement is highly relevant in the field as it will significantly expand the domain of systems that can be studied by EPR. Among such systems are biomolecules, catalytic surfaces, materials for quantum computing and others,” Dr. Mantas added. AmpliTech CEO Fawad Maqbool added that his company was looking forward to working with Amplify My Probe to help develop this innovative new product that will advance materials science and medical technology. “AmpliTech Group, Inc. is dedicated to being a driving force and leader in amplifier technology for communications and microwave applications that are part of everyday life around us,” Maqbool said. This contract has the potential to help strengthen AmpliTech’s position in an expanding market and pave the way to new opportunities for growth in the future. The global market for RF components in 2020 was valued at $23.79 billion, and is expected to grow at a CAGR of 14% through 2025, resulting in an estimated $45.05 billion market (https://ibn.fm/26TSZ). The company has plans to be a facilitator for enhancing, developing, and distributing breakthroughs in the following markets:

• High speed terrestrial and satellite terminals (SATCOM, “Internet in the Sky”)
• IoT (Internet of Things)
• Quantum supercomputers and research
• Autonomous self-driving vehicles
• Drones, AUVs (unmanned aerial vehicles)
• Military and defense ECM/EW
• 5G/Wi-Fi6E and 6G wireless infrastructure (cellular base stations, small cells, private Wi-Fi networks)
• Cloud farms, big data, and MEC architecture
• Deep space astronomy
• Telemedicine, AR/VR (augmented and virtual reality)
• Cybersecurity

AmpliTech recently announced that since the company uplisted to NASDAQ on February 17, 2021, it has raised more than $30 million in capital. The company believes that this is a sign of validation of its strategic growth plan among the investment community (https://ibn.fm/wDoNo). “We are pleased to see the level of interest by so many investors in these capital raises,” Maqbool said. “We have raised this capital to strengthen the Company financially and thus be better positioned to fulfill larger orders and broaden our customer base.” With the proceeds, AmpliTech plans to allocate funding, funneling it into specific endeavors. Among the potential uses of the $30 million raised, the company plans to focus on:

• Funding organic growth by sales force expansion and boosting the business development and marketing efforts,
• Expanding the production capabilities while strengthening the operations team,
• Making strategic acquisitions or acquire complementary intellectual properties,
• Funding additional research and development efforts to sustain continued organic growth, and
• Purchasing capital equipment to increase production efforts for productivity and engineering support.

The current investments into AmpliTech allow the company to pay down debt and use cash (and non-dilutive methods) for M&A activities aimed at building a world that the company envisions sustaining through its proprietary technology designed to improve everyone’s quality of life – whether it be through smart homes, cities, or high-speed 5G connectivity. For more information, visit the company’s website at www.AmpliTechInc.com. NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG

June 3-4th, 2021 DGE’s Risk-Based Quality Management Summit June 3-4th, 2021 On 3rd -4th June 2021, biopharma and medical device companies are invited to attend the Live Streaming of the Risk-Based Quality Management Summit. The event is hosted by Dynamic Global Events (“DGE”), a Life Science Leader in organizing B2B Events. The Global Event Company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries. The 2-day event will start with the chairperson’s opening remarks followed by a keynote on World-Class Enterprise Risk Evaluation and Adaptive Monitoring provided Andy Lee, SVP, Head of Global Clinical Trials Operations at Merck Research Laboratories. Experts will share insights proactive risk management, quality my design and data monitoring. This Summit aims to discuss risk tolerance and agility in clinical trial oversight. The RBQM Summit will provide all the latest information that will help reduce the complexity and costs associated with clinical trials, cutting down the risks involved, to derive the maximum output from the R&D budget. The Risk-Based Quality Management Summit will include two sessions on COVID-19 with Phi Tat, Central Monitoring Manager, Pfizer (NASDAQ: PFE), and Jennifer Goewey, Associate Director, Risk Management-Central Monitoring, Janssen R&D, to address the impact of COVID19 on trials. The Summit will focus on complex issues, including: o How to design a comprehensive RBQM master plan on Streamline a “culture of quality” for proactive risk management to Discern the realities of applying Six Sigma to clinical research to Assess the situation when thresholds are exceeded and whether subsequent data are still valid to Evaluate remote monitoring of data and examine changes in clinical trial landscape post COVID-19 o Exacting a risk-based audit strategy and prepare to ensure inspection readiness The distinguished speaking faculty of the Summit consists of 15 imminent influencers from the pharma industry and risk-management experts. Andy Lee, Merck Research Laboratories, SVP, Head of Global Clinical Trials Operations; Andy Lawton, Risk-Based Approach Ltd, Consultant; Angela Repa, bluebird bio (NASDAQ: BLUE), Senior Director, Proactive Clinical Excellence; Anne Lawrence, AbbVie (NASDAQ: ABBV), Executive Director Site Management Operations; Celeste Gonzalez, Boston Scientific, Principal Specialist, Clinical Quality Assurance and Compliance; Shawntel Swannack, GSK (NASDAQ: GSK), Central Monitoring, to name a few. In these uncertain times, this Summit offers in depth and fresh perspectives on RBQM. It will provide an opportunity for World-Class Risk Evaluation and Adaptive Integrated Monitoring that will help conserve energy and resources and maintain agility in clinical trial oversight. For more information regarding the event, please visit https://ibn.fm/6bglf

• Consequences of novel Coronavirus infection on brain health are significant, requiring frequent brain monitoring
• Brain diagnostics in infected patients extremely limited due to their severe physical illnesses; traditional EEG time consuming, exposes frontline workers to virus transmission risk
• BRSF’s sanitary disposable NeuroCap(TM) helps health care workers get quick, reliable insights into patient’s condition while minimizing cross-contamination risk

Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company providing next-gen solutions to the neurology market, is poised to offer a response to brain diagnostic challenges in the hospitals’ red zones amid the pandemic. As the Company describes in one of the recent articles published on the website, the consequences of the COVID-19 pandemic on brain health are significant (https://ibn.fm/fhYxm).

While respiratory damage of novel Coronavirus is well reported, debilitating and even deadly neurological conditions may be affecting far more people infected with the virus. As the pandemic unravels and we learn more about the COVID-19, it is becoming clear that, although COVID-19 does not appear to directly attack nerve tissue, it is neurologically damaging. It is known to cause neurological injury in 1 out of 7 patients hospitalized with the infection (https://ibn.fm/aTUhK). The list of neurological diseases associated with COVID-19 infection is long and includes encephalopathy, Guillain-Barré syndrome, hemorrhagic stroke, ischemic stroke, meningoencephalitis, paralysis, and seizures. A growing body of evidence suggests that COVID-19 can have serious and potentially long-lasting effects on the brain — as many as 1 in 3 COVID-19 survivors experience neurological or a mental health disorder within six months of the infection (https://ibn.fm/Bop48).

COVID-19 appears to cause neurological injury through three mechanisms, including hypoxemia — the state of very low blood oxygen levels causing encephalopathy and neurological damage; immune dysfunction causing “cytokine storm” and blood clots.

Neurological conditions associated with COVID-19 are challenging to diagnose. For example, the diagnosis of encephalopathy, one of the most frequently occurring neurological conditions in COVID-19, is mainly clinical and heavily hindered by the severe physical illnesses of hospitalized infected patients. Investigative procedures such as MRI, lumbar puncture and cerebrospinal fluid analysis are complicated to perform on ICU patients that are on supportive care measures such as mechanical ventilation and supplemental oxygenation.

The quest for a diagnostic procedure that may offer a response in this extremely difficult and limiting setting is still ongoing – but EEG may be able to offer a solution.

EEG could be a potentially helpful study to conduct on patients with suspected COVID-19 encephalopathy. Bedside EEG testing may reveal occult, subclinical seizure activity that would otherwise go unveiled. Still, traditional EEG testing is a time-consuming task that requires placing electrodes and measuring the patient’s head, which all prolongs exposure of frontline health workers to the deadly virus.

When fighting a highly contagious disease, disposable technology is vital. This is where NeuroCap(TM) and NeuroEEG(TM), the Company’s two FDA-cleared devices, can help. They offer cost-efficient, portable neurological monitoring. With sanitary, disposable EEG caps, BRSF’s revolutionary solution helps health care workers get a quick, reliable picture of a patient’s condition while ensuring that the virus is not spread through equipment. BRSF’s EEG caps designed for single use are also easy to place – within minutes – which helps shorten person-to-person exposure, minimizing cross-contamination risk between staff and patients.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• The BevCanna team has decades of combined experience creating, branding and manufacturing iconic brands that resonate with consumers on a global scale
• BevCanna owns and operates world class infrastructure, including a 40,000-square-foot, HACCP certified manufacturing facility with a current bottling capacity of up to 210 million bottles per year for both traditional and cannabis-infused beverages, and an alkaline spring water aquifer located onsite
• The company delivers a diverse portfolio of beverages and nutraceuticals for both in-house brands and white labeled products
• BevCanna leverages a proven direct-to-consumer e-commerce strategy to sell a range of natural health products throughout North America and Western Europe
• The company has provided strong revenue guidance through multiple streams, including white labeling, joint-ventures, licensing, brand building and e-commerce direct to consumer

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) is a diversified health & wellness beverage and natural products company focused on developing and manufacturing a range of plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. The BevCanna team boasts decades of experience creating, manufacturing and distributing iconic brands that resonate with consumers on a global scale. BevCanna’s distribution network features more than 3,000 points of retail distribution through the company’s market-leading TRACE brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network and its partnership with #1 U.S. cannabis beverage company Keef Brands. Based in British Columbia, Canada, BevCanna was founded in 2017. End-to-End Turnkey Beverage Manufacturing Solutions BevCanna is a manufacturer of traditional and cannabis-infused beverage brands serving a growing roster of white-label clients, in addition to operating a portfolio of in-house and partner brands. The company offers a full-service white label beverage manufacturing solution.

• Processing – At its state-of-the-art beverage manufacturing facility, BevCanna partners with industry leaders specializing in crude extraction, refinement, purification and solubility conversion to provide high-quality water-immiscible emulsions that maximize bioavailability, clarity and taste.
• Spring Water – BevCanna directly owns a pristine naturally alkaline spring water aquifer in British Columbia.
• Product Development – BevCanna leverages its expertise to develop captivating flavors based on category and consumer insights in order to enhance product positioning.
• Packaging – A variety of packaging options are offered by BevCanna, including beverage and nutraceutical formats such as PET, aluminum and glass, available in a variety of standard and custom sizes and shapes.
• Beverage Manufacturing: Traditional & Cannabis Facilities – The company’s 40,000-square-foot beverage manufacturing facility is HACCP (Hazard Analysis Critical Control Point) Certified. The facility’s capabilities include blow molding, dosing, carbonation options, filling and capping, pressure sensitive and shrink-sleeve label applications, flash pasteurization, QA testing and packing/palletizing for shipment.

Pure Therapy, TRACE and Partner Brands BevCanna’s in-house brands include Pure Therapy and TRACE. Pure Therapy is a direct-to-consumer e-commerce brand that markets a range of natural health products, including nutraceuticals and hemp-based cannabidiol (“CBD”) products, throughout North America and Western Europe. Pure Therapy has secured orders from over 23,000 customers since its inception in 2017. BevCanna expects strong growth through Pure Therapy over the next 12 months driven by new product integration, accelerated growth of existing products and its marketing team’s e-commerce expertise. TRACE products feature the Naturo Group’s proprietary plant-based fulvic and humic mineral formula, sourced from deep within the Rocky Mountains of interior British Columbia. These unique and ancient minerals provide wellness properties that include iron, magnesium, calcium, potassium and many other minerals no longer found in our food chain at adequate levels. Research suggests that the proprietary fulvic and humic organic compounds found in TRACE products could offer a number of key benefits, including promoting gut health, immune function, cognitive performance and whole-body wellness. TRACE products include Natural Alkaline Spring Water, Plant-Based Mineralized Spring Water, Natural Flavor Sparkling Spring Water, Plant-Based Mineral Concentrate with Vitamin D and Plant-Based Mineralized Immune Support Shots. In addition to its in-house brands, BevCanna provides white-label services to a number of partners in its space. BevCanna’s current portfolio of brand partnerships includes #1 U.S. cannabis beverage brand Keef (cannabis-infused classic soda) and BLOOM (live resin & high-end extracts). BevCanna also has multiple white label agreements to co-manufacture branded beverages. Market Outlook for Cannabis-Infused Beverages In 2018, the cannabis-infused beverage market was valued at $901.8 million. The market is expected to grow during the forecast period of 2019 to 2025 at a CAGR of 17.8%, resulting in a market value in excess of $2.84 billion by 2025, according to Grand View Research (https://ibn.fm/VkJfH). The projected growth is largely attributed to the legalization of recreational and medical marijuana in multiple jurisdictions. Cannabis-infused beverages are uniquely positioned to provide an alternative to a large portion of the edibles market, including items such as chocolates, cookies, gummies and other types of confectionery pieces. Management Team Marcello Leone is the CEO and Founder of BevCanna. He is also the founder of Naturo Group and the TRACE brand. John Campbell is the CFO and CSO of BevCanna. He has over 30 years of experience in the investment industry, including time with TriView Capital Ltd. Keith Dolo is the company’s Executive Management Advisor, having previously served as CEO and Executive Chairman of Sproutly Inc. Previously, he served for over 13 years with Robert Half (NYSE: RHI), an S&P 500 company, specifically in the role of Vice President for the last eight years. Melise Panetta is the company’s President. She is an accomplished senior marketing and sales executive with extensive experience leading organizations such as SC Johnson, General Mills (NYSE: GIS) and PepsiCo (NASDAQ: PEP). Ms. Panetta has nearly 15 years of deep marketing and sales expertise. Raffael Kapusty is the company’s Vice President of Sales & Insights. She is an accomplished CPG industry leader with more than 25 years of experience in both the Canadian and U.S. retail spaces. With a solid foundation at ACNielsen Canada (NYSE: NLSN), Ms. Kapusty has developed a deep understanding of the CPG space, working with over 100 leading Canadian & global CPG manufacturers. She has also held senior category and key account management roles at Kroger (NYSE: KR), SC Johnson and Unilever Canada (NYSE: UL). Bill Niarchos is the company’s Vice President of Sales & Sales Operations. He has over 20 years of experience in the CPG goods industry/retail environment. In his most recent role as Director of Sales with Bayer Consumer Health, Mr. Niarchos managed the strategic direction and growth of Loblaw & SDM. Prior to his position with Bayer (ETR: BAYN), Mr. Niarchos held a number of progressive roles at Colgate Palmolive (NYSE: CL) for more than 14 years. Japheth Noah is the company’s Head of Quality Assurance. He is an Oxford and MIT educated quality and regulatory manager with over 15 years of experience in the beverage, pharmaceutical, natural health and medical industries. Keith Stride is the company’s Creative Director. He has 25 years of experience in marketing and advertising, including time in a CMO role with Hemptown USA. Mr. Stride is internationally recognized for building high-profile brands, including Rogers (NYSE: RCI), TD Bank (NYSE: TD), Best Buy (NYSE: BBY), Whistler-Blackcomb and RBC (NYSE: RY). For more information, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

• Nextech recently signed a letter of intent to acquire all outstanding shares of Threedy.ai Inc. Threedy’s AI-enabled technologies create 3D models from 2D images through a six-stage assembly line, integrated into a single platform. Nextech intends to assimilate Threedy’s platform into its AR ecosystem
• The company also announced it has been designated as the preferred vendor by Visit Tampa Bay, a not-for-profit organization
• NTAR recently launched “LiveX,” its Digital Experience Platform, and plans to showcase it in a June 29 signature event featuring Gary Vee as the keynote speaker

Toronto-based Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF) recently announced it has signed a binding LOI to acquire all outstanding shares of California-based Threedy.ai Inc (“Threedy”). The acquisition, expected to be completed mid-June, will be based on an all-stock offer in which US$9.5 million worth of Nextech’s common shares will be issued to Threedy’s shareholders (https://ibn.fm/bg5PZ). Founded in 2018, Threedy envisions a commerce world wherein every physical product has an exact 3D digital replica. To achieve this vision, the startup builds proprietary artificial intelligence (“AI”) technologies and computer vision innovations that create 3D models of physical products from 2D photos at scale through a six-stage assembly line. The 3D model creation process, carried out within a single integrated platform, starts with the automatic onboarding of product photos using a simple JavaScript tag. The AI then creates 3D models of each item, which are hosted on Threedy’s cloud. The platform subsequently serves 3D visualizations using web-based augmented reality (“AR”) or 3D viewing applications. These steps can be summarized as ingest, segment, create, paint, assemble, and package. This AI-enabled product, coupled with the guidance of the leadership team comprising seasoned entrepreneurs and scientists, has enabled Thready to forge relationships with many clients in the commerce industry, including Wayfair, Walmart, Lighting Plus New Zealand, K-mart Australia, Kohl’s Pier 1 Imports, and more. With the buyout, which is part of Nextech’s acquisition strategy to create new revenue opportunities and grow, Nextech intends to assimilate Threedy’s AI-powered integrated platform into its AR ecosystem. It envisions that this product will become the self-service AR platform for all its AR solutions, which include holograms, AR portals, e-commerce, AR advertising, and more. Further, the acquisition will enable both Nextech and Threedy to bridge the content creation gap between 2D and 3D and center AI technology within the digital transformation economy. “With Threedy’s technology and Nextech’s global sales and marketing machine, our combined AI teams, and our existing AR tech and resources as a public company, I’m convinced that we will quickly take a leadership position in the AR industry,” stated Nextech CEO Evan Gappelberg. As a developer of a better industry solution for creating 3D models and content, Threedy is well placed to scale with the rapid adoption of AR around the world. In fact, the startup’s game-changing product is the first ever to create digital replicas easily, fast, and cost-effectively manner. It, therefore, significantly benefits major retailers and manufacturers, which, for a long time, could not expand their 3D digital inventories fast enough and cost-effectively. At the time, the biggest bottleneck used to be the inability to create 3D models at a scale. But not any longer. Elsewhere, Nextech also made two notable announcements recently, the first being that it has been chosen as the preferred vendor by Visit Tampa Bay, a not-for-profit organization that encourages visitors to unlock the sun, fun, and culture in Florida’s most diverse travel destination (https://ibn.fm/mWniD). While the partnership mainly concerns Nextech’s e-commerce segment, it is strategic because it extends the company’s reach by providing an opportunity to connect with confirmed conferences to host virtual and hybrid events on its virtual experience platform (“VXP”). Additionally, on May 12, NTAR released its Digital Experience Platform, “LiveX”, the AR industry’s first-ever all-in-one platform that supports AR advertising, AR e-commerce, AR products, and augmented digital experiences. The company plans to showcase LiveX in a signature event, dubbed “LiveNow,” to be held Tuesday, June 29, 2021, at 10 am Eastern Time (https://ibn.fm/foRW2). LiveNow will feature entrepreneur and internet personality Gary Vaynerchuk (better known as Gary Vee) as the keynote speaker. For more information, visit the company’s website at www.NextechAR.com. NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF